Impact of a Cystic Fibrosis Specific Multivitamin Formulation on Fat-Soluble Vitamin Status and Treatment Satisfaction in Young Children

Background: Children with cystic fibrosis (CwCF) are at increased risk of fat-soluble vitamin (FSV) deficiency due to fat malabsorption. In France, children were usually supplemented with multiple individual vitamin preparations but have recently converted to DEKAs Plus Liquid (DPL), an absorption-enhanced, CF-specific, multivitamin formulation that includes vitamins D3, E, K1, A (beta-carotene and retinol), B, C, zinc, and selenium. We evaluated the impact of this change on FSV levels, treatment satisfaction, and compliance. Methods: Young CwCF (n = 39, mean age 2.3 ± 1.1 years) were analyzed retrospectively. Serum FSV levels, prothrombin time, treatment satisfaction, and compliance were assessed at baseline (M0) and after 12 months (M12). Results: Paired data analysis was performed on the 34 who completed 12 months. After 3 months, the initial daily dose was adjusted in nine cases. Median (interquartile range) serum levels of vitamin E (19.3 (17–27) vs. 26.3 (20–31) µmol/L, p = 0.0002) and 25-hydroxyvitamin D (80.2 (68–91) vs. 88.5 (79–108) nmol/L, p = 0.04) increased. Prothrombin time and vitamin A levels showed no significant change (p = 0.7, p = 0.4, respectively). The total number of FSV deficiencies decreased from 10 to 1, vitamin D deficiency was eliminated, and vitamin K1 supplementation increased from 76% to 100% (p = 0.008). The median treatment satisfaction score (VAS1–10) improved from 7 (5–9) to 9 (9–10) (p = 0.0006). Patient compliance remained high (9.5 (8.5–10) vs. 10 (9–10), p = 0.4). Conclusions: Switching from individual vitamins to DPL reduced vitamin deficiencies and improved FSV levels and patient satisfaction.